Methods of providing solriamfetol therapy to subjects with impaired renal function
AssigneeAxsome Malta Ltd.
InventorsKatayoun Zomorodi, Herriot Tabuteau
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
Claims13
A method of reducing toxicity due to [R]-2-amino-3-phenylpropylcarbamate (APC), said method comprising selecting a subject having normal renal function ingesting more than a therapeutically effective dose of APC, wherein the APC is the form of a hydrochloride salt, and administering hemodialysis to the subject in a 12 hour session.
Dependencies are inferred from the claim text.